Iloprost and echistatin protect platelets during simulated extracorporeal circulation.
Temporary, reversible inhibition of platelets during cardiopulmonary bypass is an attractive strategy to protect platelets and normalize postoperative bleeding times. Iloprost, an analogue of prostacyclin, and the disintegrins reversibly inhibit platelets by different mechanisms. We tested the hypothesis that reduced doses of iloprost and either echistatin, a natural disintegrin, or RO43-5054, a peptidomimetic, in combination provide better platelet protection than any drug alone during simulated extracorporeal circulation. Thirty-five recirculation studies using fresh, heparinized human blood in an extracorporeal perfusion circuit that contained a 0.45-m2 spiral coil membrane oxygenator were performed. Iloprost, but neither echistatin nor RO43-5054, increased platelet cyclic adenosine monophosphate. Combinations of iloprost and either fibrinogen receptor antagonist at reduced doses submaximally increased platelet cyclic adenosine monophosphate. Platelet adhesion and release of beta-thromboglobulin antigen was completely inhibited by combinations of the two classes of drugs, but only partially inhibited by each drug alone. Combinations of drugs also completely inhibited platelet aggregation to adenosine diphosphate; these platelets retained full sensitivity to adenosine diphosphate after 90 minutes of recirculation when drugs were removed by gel filtration. We conclude that combinations of iloprost and a fibrinogen receptor antagonist at doses that are unlikely to produce clinical side effects completely inhibit platelet activation and preserve platelet function during in vitro extracorporeal circulation.
Bernabei
A
A
Harrison Department of Surgery, School of Medicine, University of Pennsylvania, Philadelphia.
Gikakis
N
N
Kowalska
M A
MA
Niewiarowski
S
S
Edmunds
L H
LH
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002315:Cardiopulmonary Bypass; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000097:blood; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D016285:Iloprost / Q000494:pharmacology*; D066298:In Vitro Techniques; D036341:Intercellular Signaling Peptides and Proteins; D009842:Oligopeptides / Q000494:pharmacology; D010455:Peptides; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D014757:Viper Venoms / Q000494:pharmacology*; D001620:beta-Thromboglobulin / Q000378:metabolism
D036341:Intercellular Signaling Peptides and Proteins; D009842:Oligopeptides; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D014757:Viper Venoms; D001620:beta-Thromboglobulin; C057986:echistatin; C078174:Ro 43-5054; D005576:Colforsin; D000244:Adenosine Diphosphate; D000242:Cyclic AMP; D016285:Iloprost; D004837:Epinephrine